RU2019130661A - Анти-pd-l1 антитело для детекции pd-l1 - Google Patents

Анти-pd-l1 антитело для детекции pd-l1 Download PDF

Info

Publication number
RU2019130661A
RU2019130661A RU2019130661A RU2019130661A RU2019130661A RU 2019130661 A RU2019130661 A RU 2019130661A RU 2019130661 A RU2019130661 A RU 2019130661A RU 2019130661 A RU2019130661 A RU 2019130661A RU 2019130661 A RU2019130661 A RU 2019130661A
Authority
RU
Russia
Prior art keywords
amino acid
acid sequence
seq
antibody
light chain
Prior art date
Application number
RU2019130661A
Other languages
English (en)
Other versions
RU2019130661A3 (ru
RU2758723C2 (ru
Inventor
Сатору КОННАИ
Кадзухико ОХАСИ
Сиро МУРАТА
Томохиро ОКАГАВА
Асами НИСИМОРИ
Наоя МАЕКАВА
Сатоси ТАКАГИ
Юмико КАГАВА
Ясухико СУДЗУКИ
Тие НАКАДЗИМА
Original Assignee
Нэшнл Юниверсити Корпорейшн Хоккайдо Юниверсити
Фусо Фармасьютикал Индастриз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нэшнл Юниверсити Корпорейшн Хоккайдо Юниверсити, Фусо Фармасьютикал Индастриз, Лтд. filed Critical Нэшнл Юниверсити Корпорейшн Хоккайдо Юниверсити
Publication of RU2019130661A3 publication Critical patent/RU2019130661A3/ru
Publication of RU2019130661A publication Critical patent/RU2019130661A/ru
Application granted granted Critical
Publication of RU2758723C2 publication Critical patent/RU2758723C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (31)

1. Антитело против PD–L1, содержащее
(а) легкую цепь, содержащую
CDR1 с аминокислотной последовательностью KSISKY (SEQ ID NO:1),
CDR2 с аминокислотной последовательностью SGS и
CDR3 с аминокислотной последовательностью QQHNEYPLT (SEQ ID NO:2) и
(b) тяжелую цепь, содержащую
CDR1 с аминокислотной последовательностью GYTFTDYI (SEQ ID NO:3),
CDR2 с аминокислотной последовательностью INPDSGGN (SEQ ID NO:4) и CDR3 с аминокислотной последовательностью ARGITMMVVISHWKFDF (SEQ ID NO:5).
2. Антитело по п.1, которое получено у крысы.
3. Антитело по п.2, которое представляет собой крысиное анти–бычье антитело PD–L1.
4. Антитело по п.3, где
вариабельная область легкой цепи имеет аминокислотную последовательность SEQ ID NO:6 и
вариабельная область тяжелой цепи имеет аминокислотную последовательность SEQ ID NO:7.
5. Антитело по любому из пп.1–4, где вариабельная область легкой цепи имеет аминокислотную последовательность вариабельной области каппа легкой цепи.
6. Антитело по любому из пп.1–5, где константная область тяжелой цепи имеет аминокислотную последовательность константной области IgG2a.
7. Антитело по п.5 или 6, где
константная область легкой цепи имеет любую аминокислотную последовательность SEQ ID NO:8, 10–12, и
константная область тяжелой цепи имеет любую аминокислотную последовательность SEQ ID NO:9 или 13.
8. Антитело по любому из пп.1–7, которое имеет структуру на основе четырех цепей, состоящую из двух легких цепей и двух тяжелых цепей.
9. Композиция для детекции PD–L1, содержащая антитело по любому из пп.1–8 в качестве активного ингредиента.
10. Композиция по п.9 для применения для диагностики злокачественных новообразований и/или воспалений.
11. Композиция по п.10, где злокачественные новообразования и/или воспаления выбраны из группы, состоящей из неопластических заболеваний, лейкемии, болезни Джона, анаплазмоза, бактериального мастита, микотического мастита, микоплазменных инфекций (таких как микоплазменный мастит, микоплазменная пневмония или подобных), туберкулеза, инфекции, вызыванной Theileria orientalis, криптоспоридиоза, кокцидиоза, трипаносомоза и лейшманиоза.
12. Композиция по п.9 для применения для селекции животных, подходящих для терапии анти–PD–L1 антителами.
13. ДНК, кодирующая антитело против PD–L1 по п.1.
14. Вектор, содержащий ДНК по п.13.
15. Клетка–хозяин, трансформированная вектором по п.14.
16. Способ получения антитела, включающий культивирование клетки–хозяина по п.15 и сбор анти–PD–L1 антитела выше из полученной культуры.
17. ДНК, кодирующая легкую цепь антитела против PD–L1, где указанная легкая цепь содержит
CDR1 с аминокислотной последовательностью KSISKY (SEQ ID NO:1), CDR2 с аминокислотной последовательностью SGS и CDR3 с аминокислотной последовательностью QQHNEYPLT (SEQ ID NO:2).
18. ДНК, кодирующая тяжелую цепь антитела против PD–L1, где указанная тяжелая цепь содержит
CDR1 с аминокислотной последовательностью GYTFTDYI (SEQ ID NO:3), CDR2 с аминокислотной последовательностью INPDSGGN (SEQ ID NO:4) и CDR3 с аминокислотной последовательностью ARGITMMVVISHWKFDF (SEQ ID NO:5).
RU2019130661A 2017-03-27 2018-03-23 Анти-pd-l1 антитело для детекции pd-l1 RU2758723C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017061389 2017-03-27
JP2017-061389 2017-03-27
PCT/JP2018/011895 WO2018181064A1 (ja) 2017-03-27 2018-03-23 Ｐｄ－ｌ１検出用抗ｐｄ－ｌ１抗体

Publications (3)

Publication Number Publication Date
RU2019130661A3 RU2019130661A3 (ru) 2021-04-28
RU2019130661A true RU2019130661A (ru) 2021-04-28
RU2758723C2 RU2758723C2 (ru) 2021-11-01

Family

ID=63675642

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019130661A RU2758723C2 (ru) 2017-03-27 2018-03-23 Анти-pd-l1 антитело для детекции pd-l1

Country Status (14)

Country Link
US (2) US10865246B2 (ru)
EP (1) EP3604539A4 (ru)
JP (1) JP7036388B2 (ru)
KR (1) KR102402398B1 (ru)
CN (1) CN110418842B (ru)
AU (1) AU2018242880B2 (ru)
BR (1) BR112019019077A2 (ru)
CA (1) CA3056045A1 (ru)
MX (1) MX2019010555A (ru)
MY (1) MY197497A (ru)
PH (1) PH12019502023A1 (ru)
RU (1) RU2758723C2 (ru)
SG (1) SG11201908543WA (ru)
WO (1) WO2018181064A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3604539A4 (en) 2017-03-27 2020-12-23 National University Corporation Hokkaido University ANTI-PD-L1 ANTIBODIES FOR DETECTION OF PD-L1
AR118619A1 (es) * 2019-04-10 2021-10-20 Bio Thera Solutions Ltd Anticuerpos de unión a pd-1
WO2023219147A1 (ja) * 2022-05-13 2023-11-16 塩野義製薬株式会社 Ｃｃｒ８検出用新規抗ｃｃｒ８抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2385115A (en) 1940-11-27 1945-09-18 Mechanical Handling Sys Inc Haulaway trailer construction
JPS53106853A (en) 1977-02-28 1978-09-18 Yokohama Rubber Co Ltd Wire for reinforcing rubber wares
RU2478400C2 (ru) * 2006-12-27 2013-04-10 Эмори Юниверсити Композиции и способы лечения инфекций и опухолей
WO2010074080A1 (ja) 2008-12-22 2010-07-01 国立大学法人北海道大学 動物細胞を用いて外来遺伝子由来タンパク質を大量に生産するための発現ベクター、およびその利用
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CN111499755A (zh) * 2012-08-03 2020-08-07 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
AU2014339900B2 (en) * 2013-10-25 2019-10-24 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
US10280223B2 (en) * 2014-07-09 2019-05-07 Nippon Zenyaku Kogyo Co., Ltd. Anti-canine PD-1 antibody or anti-canine PD-L1 antibody
RU2722562C2 (ru) 2014-09-30 2020-06-01 Интервет Интернэшнл Б.В. Антитела к pd-l1, связывающие pd-l1 собаки
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
JP6635290B2 (ja) 2015-09-24 2020-01-22 日本電気硝子株式会社 ガラス材及びその製造方法
EP3604539A4 (en) 2017-03-27 2020-12-23 National University Corporation Hokkaido University ANTI-PD-L1 ANTIBODIES FOR DETECTION OF PD-L1

Also Published As

Publication number Publication date
RU2019130661A3 (ru) 2021-04-28
SG11201908543WA (en) 2019-10-30
JP7036388B2 (ja) 2022-03-15
AU2018242880B2 (en) 2024-05-16
BR112019019077A2 (pt) 2020-04-22
RU2758723C2 (ru) 2021-11-01
CA3056045A1 (en) 2018-10-04
US11697686B2 (en) 2023-07-11
US20210079095A1 (en) 2021-03-18
US20200031932A1 (en) 2020-01-30
AU2018242880A1 (en) 2019-10-31
PH12019502023A1 (en) 2020-03-16
KR102402398B1 (ko) 2022-05-25
US10865246B2 (en) 2020-12-15
CN110418842B (zh) 2023-05-02
MY197497A (en) 2023-06-19
KR20190132651A (ko) 2019-11-28
EP3604539A4 (en) 2020-12-23
EP3604539A1 (en) 2020-02-05
CN110418842A (zh) 2019-11-05
MX2019010555A (es) 2019-12-11
WO2018181064A1 (ja) 2018-10-04
JPWO2018181064A1 (ja) 2020-02-27

Similar Documents

Publication Publication Date Title
RU2019105702A (ru) Антитело против lag-3
RU2019132843A (ru) Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение
HRP20201975T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
RU2019130661A (ru) Анти-pd-l1 антитело для детекции pd-l1
JP2020536488A5 (ru)
HRP20231579T1 (hr) Anti-ctla-4 antitijela i postupci njihove upotrebe
RU2016129274A (ru) Канинизированные мышиные антитела к человеческому pd-1
RU2020124623A (ru) Антитела, специфичные к гетеродимеру cd3-дельта/эпсилон
RU2017105915A (ru) Антитела против pd-1
RU2017145268A (ru) Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов
RU2018146533A (ru) Антитела к cd40 и пути их применения
RU2014101707A (ru) АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
RU2016100892A (ru) Антитела против tweakr и их применение
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
RU2016138744A (ru) Антитела, фармацевтические композиции и их применения
RU2013135175A (ru) Фармацевтическая композиция комплекса антитела против дигоксигенина и дигоксигенина, конъюгированного с пептидом
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
RU2012105045A (ru) Моноклональное антитело человека против альфа-токсина из s. aureus и его применение в лечении или предотвращении образования абсцесса
RU2019105699A (ru) Антитело против pd-l1
JP2021500916A5 (ru)
RU2014127287A (ru) Антитела, используемые для пассивной вакцинации против гриппа
RU2019105697A (ru) Антитело против pd-l1
RU2017122172A (ru) Антитела к IL-17C
RU2016137486A (ru) Новое антитело против pai-1 человека
RU2016141285A (ru) Биспецифические антигенсвязывающие полипептиды